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polymerase (1 U/reaction) and buffer, containing 2 µl cDNA, LOH analysis. Microsatellites used for the LOH analysis were chosen as near as possible to the gene loci, using the mapping 0.2 pM each primer and 75 µM dNTP in a total volume of 50 µl. Reactions consisted of an initial denaturing step at 94°C information from Genemap99. The microsatellite markers used were as follows: hBUB1, D2S293; hBUB1B, D15S146; hBUB3, in two minutes, followed by 20 cycles of 15 s at 94°C, 30 s at 56°C and 90 s at 72°C, then 15 cycles of 15 s at 94°C, 30 s D10S587; and TTK, D6S284. Fluorescence labelled primers were obtained from DNA Technology (Denmark). The PCR at 56°C, and 90 s plus 20 s per cycle at 72°C. The reaction was terminated by 7 min at 72°C. The PCR products were reaction, containing 50 ng DNA, 0.1 pM of each primer (one primer fluorescence labeled), 10 mM Tris (pH 9.0), 50 mM then sequenced in both directions using a Big Dye Sequencing kit (PE Applied Biosystems, USA) according to the manufacKCl, 1.5 mM MgCl 2 , 150 µM dNTP and 0.5 U Taq polymerase (Amersham Pharmacia Biotech, USA) was carried out in a turers instructions, and analysed on an ABI 377 Sequencer (PE Applied Biosystems). The primer sequences used for PCR total volume of 20 µl. The PCR mix was subjected to an initial 5 min at 95°C, followed by 35 cycles of 50 s at 95°C, amplification and sequencing of hBUB1, hBUB1B, hBUB3 and TTK are available at www.mdl.dk/supplementary-data. 90 s at 58°C and 90 s at 72°C. The reaction was terminated by 5 min at 72°C. The PCR products were subsequently The sequence analysis was performed on six bladder cancer cell lines and 15 bladder tumour samples from patients analysed on an ABI 377 Sequencer (PE Applied Biosystems) using GeneScan™ software. LOH was defined as Ͼ50% with concomitant carcinoma in situ. By using RT-PCR and sequencing of cDNA, we found that all four genes were decrease in chromotogram peak height of the affected allele. At the hBUB1 locus we detected no LOH in the 15 tumour expressed and without mutations in all six cell lines and 15 tumor specimens.
samples studied, whereas we detected one LOH for each of the hBUB1B, hBUB3 and TTK loci. LOH was found in three The sequence analysis revealed several sequence variations, both new and previously published ( Table I ). The new varidifferent tumor samples. Taking into account the low number of LOH found in this ations were as follows: hBUB1B, T348→C (Tyr to Tyr); TTK, A315→G (Ile to Val) and G1117→T (Ala to Ser). All sequence investigation and the frequency of aneuploidy, it does not seem likely that a gene dose effect is an important factor in variations found during cDNA sequencing were verified by sequencing DNA extracted from blood samples from the mitotic checkpoint failure in bladder cancer. What is obvious from the present data, and from all previous mutational patients.
The two new non-silent sequence variations are both posiinvestigations of mitotic checkpoint genes, is that it is unlikely that mutations in the known mitotic checkpoint genes are the tioned in the putative regulatory or binding region of TTK. The first variant is an A→G transition at position 315 of TTK, primary source of genetic instability in cancer cells. An explanation for the observed chromosomal instability in bladder causing a shift from isoleucine to valine. Due to the close relationship between valine and isoleucine, both having hydrocancer and other types of cancer could be due to mutations in presently unknown checkpoint genes, maybe in combination phobic side chains, it is relatively unlikely that this amino acid substitution will have any impact on the function of TTK.
with other mechanisms of inactivation, such as promoter methylation or defects in possible post-transcriptional reguThe other sequence variant, a G→T transition at position 1117, changes an alanine to a serine. However, the sequence latory mechanisms. It has been previously shown that a mitotic checkpoint-deficient breast cancer cell line showed severely variation is homozygous in all six cell lines and all 15 tumour samples. Whether this sequence variant is due to an error in reduced expression of the mitotic checkpoint gene hMAD2 (15). Several sequence variations resulting in amino acid the GenBank sequence or it is a genuine sequence variation is presently unknown. differences are found in the mitotic checkpoint genes in this and previous reports. It is a possibility that specific To investigate the genomic stability of the hBUB1, hBUB1B, hBUB3 and TTK loci we performed loss of heterozygosity combinations of these sequence variations may result in reduced function of the mitotic checkpoint apparatus and (LOH) analysis on the clinical samples. DNA from tumour samples and blood from the same patient was used for the thereby an increased cancer risk. 
